Saturday, May 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A day in the life of patient advocate, Emily Ullrich

Emily Ullrich is a former professor of Communication Arts and Founder of Nairobi Film Institute, a nonprofit organization she created and where she taught filmmaking to college aged youth in Nairobi, Kenya for free. She was sick for many years before she was diagnosed with Interstitial Cystitis, Endometriosis, and Complex Regional Pain Syndrome in 2015, and Ehlers Danlos Syndrome in 2019, and has had to adapt her lifestyle according to her medical issues.

According to a study published in 2019, roughly 70% of patients diagnosed with Ehlers Danlos are women:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858200/#:~:text=We%20found%206021%20individuals%20(men,a%20practice%20of%205000%20patients.

Diagnostic criteria for the disease can be found at the following link:

https://www.ehlers-danlos.com/wp-content/uploads/2017/05/hEDS-Dx-Criteria-checklist-1.pdf

#interstitial #cystitis #endometriosis #CRPS #Ehlers #Danlos

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!